AIDS TREATMENT NEWS #340, April 7, 2000
John S. James
This unexpected announcement, an important victory for South Africa, followed a campaign by MSF (Doctors Without Borders), TAC (the Treatment Action Campaign, the main HIV/AIDS treatment activist organization in South Africa), ACT UP in the U.S., and others.
For more information, see "GIVING IT AWAY: An American Pharmaceutical Giant Offers to Donate an AIDS Drug to South Africa," by Mark Schoofs, THE VILLAGE VOICE, April 4-10, 2000.
Comment
While important, this program is limited to one country, and to one disease. And no one knows how long the company will continue it.
There are many theories as to why Pfizer was willing to offer this program, which was unexpected:
* South Africans were preparing legal action to force the company to lower its price. If successful, it might have set precedents going beyond South Africa.
* Pfizer is in merger talks to acquire Warner-Lambert, to create the world's second largest drug company; a key shareholder's meeting is April 27 in New York. The company may not want controversy which could interfere with the merger.
* People dying because they cannot afford a drug which clearly can be sold profitably at a tenth the price is a natural story for the press and television, likely to lead to endless bad publicity. South Africa is a leader in the fight for wider drug access, and news there is likely to come to world attention. Thailand already has access to an affordable generic fluconazole; most countries do not, but treatment activists are usually much less organized than in South Africa or Thailand.
* Giving a vital resource which could later be cut off creates leverage which may influence policy in the future.
* It is easier for a company to give product away than to sell it for a low price, which could lead to problems with customers who are paying more.
For all of these reasons, we believe, donating the drug made more sense to Pfizer than not doing so.
But still we do not have a model for access which is "broader and sustainable and global" [Eric Sawyer of ACT UP/New York, quoted in the VILLAGE VOICE article]. The difficulty is one of public relations. Under our system of drug development, patented pharmaceuticals need to be sold at a high markup in richer countries, to cover development and marketing expenses. At those prices, most of the world's people who need them cannot afford to buy them at all. But most drugs are inexpensive to manufacture, so access could be available at a generic price plus modest profit, either privately or through government or nonprofit programs--and corporate profits could even increase. But then those paying the high prices might complain. So millions of people are denied drugs they need and potentially could afford, in order to avoid public-relations complications for a few corporations.
Finding a path through this obstacle is a central problem of our age.
000407
ATN34003
Copyright © 2000 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .